Micro Therapeutics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Cerebral Aneurysm Multi-Center European Onyx (CAMEO) trial treats 99% (122 of 123) of aneurysms successfully, firm reports Feb. 13. Liquid embolic device hit European market in January, following MTI distribution partnership with ev3 International. In the U.S., MTI completed 30% of total case requirements for two Onyx trials as of year-end 2001, with enrollment completion targeted for the third quarter of 2002 (1"The Gray Sheet" Nov. 5, 2001, p. 26). The Irvine, California company's sales increased 54% in 2001 to $8.8 mil. A net loss of $20.1 mil. compares with a loss of $11.8 mil. in 2000...
You may also be interested in...
MTI Onyx V. Aneurysm Coil Trial Protocol Revisited; PMA On Track For 2004
Micro Therapeutics' revised inclusion criteria for its U.S. pivotal trial comparing the Onyx LES liquid embolic system with Boston Scientific's GDC Ultrasoft coil to treat brain aneurysms will delay PMA filing by three fiscal quarters, MTI estimates
MTI Aims To Rebound From Onyx Trial Delays, Focuses European Business
Micro Therapeutics, Inc.'s pivotal study of its Onyx liquid embolic system for the treatment of brain aneurysms will remain on target for completion by the third quarter of 2002, with 138 patients on board as predicted, the firm says
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.